Mutational spectrum
The spectrum described in this paragraph is based on RefSeq NM_001105. 4 .
All patients have heterozygous ACVR1 missense mutations in conserved amino acids. This disease-causing variant is a de novo mutation and therefore referred to as a mutation.
Patients with classic clinical features of FOP (great toe malformations and progressive heterotopic ossification) have previously been found to carry the same heterozygous mutation (c.617G4A; p. (Arg206His)) in the ACVR1 gene leading to an over-activation of the BMP signalling pathway. Only recently a new heterozygous ACVR1 mutation at codon 207 (c.619C4G, p.(Gln207Glu)) located in a codon adjacent to the c.617G4A, p.(Arg206His) of the ACVR1 was reported in two FOP patients with the classical phenotype. 4 Among patients with FOP-like heterotopic ossification and/or toe malformation, there are patients with clinical features unusual for FOP. These atypical FOP patients form two classes: FOP-plus (classic defining features of FOP plus one or more atypical features, predominantly associated with the classical p.(Arg206His) mutation) and FOP variants (major variations in one or both of the two classic defining features of FOP, associated with non-Arg206His mutations within the ACVR1 receptor). Novel ACVR1 mutations occur mainly in FOP variants and some cases of FOP plus. [4] [5] [6] A public list of disease causing variants is not available yet.
Analytical methods
DNA sequence analysis of protein-coding exons and splice junctions. 2 
Analytical validation
When a new mutation is found, functional testing will be necessary, like a BMP reporter assay.
1.8 Estimated frequency of the disease (incidence disease at birth ('birth prevalence') or population prevalence) 1:2 000 000. 5
1.9 If applicable, prevalence in the ethnic group of investigated person:
No ethical, racial, gender or geographic prediliction. 5
1.10 Diagnostic setting:
Comment: ad A: To differentiate from other forms of heterotopic ossification (different forms of myositis ossificans (MO), progressive osseous heteroplasia (POH) or other forms that might be confused with atypical FOP). [6] [7] [8] There are at least three other forms of MO of which the pathology is largely unknown, including MO Circumscripta, characterized by dystrophic calcification generally following severe trauma leading to heterotopic ossifications of a single intramuscular connective tissue, MO pseudo-malignant, which is limited to soft tissue and is not associated to any trauma, and a MO associated with paraplegia, closed head injury or severe trauma (non-hereditary heterotopic ossification). 7, 9 POH is characterized by progressive ossification of cutaneous, subcutaneous, and deep connective tissues and caused by an inactivation of GNAS in most cases. 10 In early stages misdiagnosis, aggressive fibromatosis or sarcoma may be suspected. Comment: ad C: Risk assessment in first generation relatives, including brothers and sisters, could be considered due to a socalled 'variant FOP' presenting with normal great toes and late-onset heterotopic ossification 11 or when one of the parents has a germ line mosaicism. 12 On the basis of the clinical and radiologic findings the diagnosis of FOP can be highly suspected, even prior to heterotopic ossifications. Characteristic toe malformations and cervical spine fusions may be diagnosed by X-ray. However, because FOP is infrequently seen by most clinicians and onset of progressive heterotopic ossification may be variable in the first decade of life, clinical misdiagnosis is common. 14,15
TEST CHARACTERISTICS

Will disease management be influenced by the result of a genetic test?
No □ Yes ⊠
Therapy (please describe)
None at the moment, but in the future some drugs might have different effects on the classical mutation or the other ACVR1 mutations. Current treatment options are only palliative and symptom-modifying. Prevention of soft tissue injury and protection against the influenza virus remain a hallmark of FOP management. 16 Prognosis (please describe)
The prognosis varies largely and depends on clinical course and severity. FOP is not only an extremely disabling disease but also a condition of shortened lifespan. The median age of the time of death is 40 years. The most common cause of death is cardiorespiratory failure (54%) from thoracic insufficiency syndrome, followed by pneumonia (15%), and complications of falls due to head injuries (11%). [17] [18] [19] Management (please describe)
Paediatricians should be aware of the early diagnostic features of fibrodysplasia ossificans progressiva, even before the appearance of heterotopic ossification. This awareness should prompt early genetic consultation and testing and the institution of assiduous precautions to prevent iatrogenic harm. 14 
Prenatal diagnosis (To be answered if in 1.10 'D' was marked)
Prenatal diagnosis should only be done for FOP patients (they have 50% risk to transmit the disease) or for parents of FOP patients, if they expect new children (risk of mosaicism in an unaffected parent). 12 3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnosis? Yes, although rare, up to three successive generations of transmissions of FOP have been described. 20 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) NA.
